Skip to main content
Premium Trial:

Request an Annual Quote

CompanionDx Taps GenomOncology to Support NGS-based Cancer Asssays


NEW YORK (GenomeWeb) – GenomOncology said this week that CompanionDX, a CLIA-certified laboratory that specializes in pharmacogenomics, cancer companion diagnostics, and targeted next-generation sequencing, will use its solution to support its suite of next-generation sequencing-based cancer assays.

GenomOncology’s GO Clincal Workbench will help researchers in CompanionDx’s lab "manage increased volume and quickly add new assays to meet the needs of our oncologists" as well as create and deliver "therapy-driven clinical reports," David Lasecki, CompanionDx’s president said in a statement.

Financial and other terms of the agreement were not disclosed.

Last week, GenomOncology said that Cleveland's University Hospitals will use the GO Clinical Workbench to launch its first next-generation sequencing-based cancer diagnostic test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.